$2.5M GRANT AWARDED TO ADVANCE WOUNDVUE™ DEVELOPMENT
• Joint collaboration with University of Melbourne and Planet Innovation Adelaide, Australia, 7 December 2017: Australian medical technology company, LBT Innovations Limited (ASX:LBT) is pleased to announce it has been awarded a $2.513 million grant to advance the…
IDT Australia Executes API Development Agreement
• API Development Agreement executed with The State Government of Victoria • Total consideration over AUD 2,000,000 over the twelve month term of the project Australian pharmaceutical manufacturing and drug development company IDT Australia Limited (ASX:IDT) announces it…
Prima BioMed has just announced new clinical data from its TACTI-mel Phase I trial in Australia – which is investigating Prima’s lead drug, IMP321, in combination with KEYTRUDA in metastatic melanoma
Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) is pleased to announce the presentation of new data from its TACTI-mel Phase I clinical trial in Australia investigating the use of eftilagimod alpha (LAG-3Ig or IMP321), the Company’s lead…
AdAlta appoints Dr Dallas Hartman as Chief Operating Officer
AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to announce the appointment of experienced executive, Dr Dallas Hartman to the role of Chief Operating Officer. Dr Hartman will bring…
Patrys and Garvan Institute of Medical Research Awarded Grant
Patrys Limited (ASX: PAB), a clinical stage biotechnology company and Sydney’s Garvan Institute of Medical Research (Garvan) have recently finalized the terms of a Federal Government Innovation Connections grant to support research within the PATDX1 program. The Garvan…
New US patent for Patrys PAT-LM1
Patrys (ASX:PAB), a clinical stage biotechnology company, has been granted a US patent for its anti-cancer pre-clinical candidate PAT-LM1. The US Patent Office has issued correspondence confirming the grant of a key patent in the PAT-LM1 family, patent…
Universal Biosensors receives $7.5M under the R&D Tax Incentive
Universal Biosensors (ASX:UBI) today announced it has received $7.5M in cash under the R&D Tax Incentive for the 2016 financial year. The R&D Tax Incentive is an Australian Government program developed to assist eligible businesses recover some of…
Medical Device Industry Sign Historic Agreement to Reduce Health Fund Premiums
The Medical Technology Association of Australia (MTAA) has signed a four-year Agreement with the Federal Government which will deliver certainty and stability to the industry and will help lower Private Health Insurance (PHI) premiums for Australians. The Agreement,…
GKC names John Schellhorn new President and CEO
GKC announced today that it has appointed John Schellhorn as its new President and CEO. Schellhorn will also be joining the company’s Board of Directors. Schellhorn joins GKC with a proven track record to spearhead the company’s accelerated…
Starpharma and Peter Mac Cancer Centre awarded DEP® Grant
Starpharma (ASX: SPL, OTCQX: SPHRY) and Peter MacCallum Cancer Centre (Peter Mac) have been awarded a further Federal Government Innovation Connections grant to support innovative research within Starpharma’s DEP® oncology program. Starpharma’s proprietary DEP® dendrimer platform improves efficacy…
LBT Receives $4.2 Million in R&D Incentives
Australian medical technology company LBT Innovations Limited (ASX:LBT) has received an R&D Incentive, net of income tax payable, of $3.98 Million for the financial year ended 30 June 2017. In addition, LBT has also received $0.22 Million for…
Starpharma – DEP® docetaxel positive phase 1 results; phase 2 commences
DEP® docetaxel phase 1 trial successfully completed with phase 2 to commence immediately DEP® docetaxel patients had no reports of neutropenia, a life-threatening toxicity seen in virtually all patients treated with conventional docetaxel formulations (e.g. Taxotere®) Encouraging signs of efficacy observed…
